1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System is sponsored by National Institutes of Health (NIH) - BRAIN Initiative. This funding opportunity supports first-in-human or early-stage clinical studies of innovative devices for recording and/or stimulating the human central nervous system.
The goal is to accelerate the translation of next-generation neurotechnologies into clinical research, addressing both therapeutic and basic neuroscience questions.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Encourages collaborations between clinical investigators and device manufacturers. Confirm the full requirements in the official notice before applying.
The current listing shows $10,000,000 (estimated total program funding; ~3 awards expected). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System are due January 1, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System is funded by National Institutes of Health (NIH) - BRAIN Initiative. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) - BRAIN Initiative. This grant encourages applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. This directly relates to technological innovation for understanding neurological processes, which can encompass neurodiversity.
BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) - BRAIN Initiative. This funding announcement from the BRAIN Initiative seeks transformative, cutting-edge, and innovative research that embraces new technologies, ideas, and approaches to understand brain circuit function and contributions to behavior.
RFA-EB-28-004, NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18), puts about $6 million into 8 to 12 BRAIN and HEAL Initiative device-development awards. Budgets should rarely exceed $750,000 in direct costs a year, projects run up to three years, nine institutes participate, and there are six due dates from February 1, 2027 through February 1, 2030. Here is what the program requires and how to write a competitive application.
Read articleNIH's RFI on administrative burden (NOT-OD-26-118) takes comments through December 8, 2026. It asks seven questions, lists eight reforms already made, and warns that responses may be posted unredacted. Here is what NIH is really asking for, what it can and cannot change alone, and how researchers and research offices should respond.
Read articleOn November 2, 2026, NIH released NOT-OD-27-006, a draft update to its Policy for Data and Safety Monitoring. As summarized by Harvard's research integrity office, the draft would extend risk-based monitoring from clinical trials to all NIH-supported clinical research, drop the blanket DSMB requirement for Phase 3 and multi-site trials, and require an NIH-approved monitoring plan scaled to risk, effective for applications six months after the final policy. Comments are due January 6, 2027. What it changes and how to respond.
Read article